ATE506374T1 - Exprimierungskontrolle unter verwendung von variabelen intergenischen sequenzen - Google Patents

Exprimierungskontrolle unter verwendung von variabelen intergenischen sequenzen

Info

Publication number
ATE506374T1
ATE506374T1 AT02785614T AT02785614T ATE506374T1 AT E506374 T1 ATE506374 T1 AT E506374T1 AT 02785614 T AT02785614 T AT 02785614T AT 02785614 T AT02785614 T AT 02785614T AT E506374 T1 ATE506374 T1 AT E506374T1
Authority
AT
Austria
Prior art keywords
expression control
intergenic sequences
variable
variable intergenic
present
Prior art date
Application number
AT02785614T
Other languages
English (en)
Inventor
Andrew POPPLEWELL
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE506374T1 publication Critical patent/ATE506374T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Mushroom Cultivation (AREA)
  • Electrotherapy Devices (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02785614T 2001-12-05 2002-12-05 Exprimierungskontrolle unter verwendung von variabelen intergenischen sequenzen ATE506374T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129105.3A GB0129105D0 (en) 2001-12-05 2001-12-05 Expression control using variable intergenic sequences
PCT/GB2002/005466 WO2003048208A2 (en) 2001-12-05 2002-12-05 Expression control using variable intergenic sequences

Publications (1)

Publication Number Publication Date
ATE506374T1 true ATE506374T1 (de) 2011-05-15

Family

ID=9927042

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02785614T ATE506374T1 (de) 2001-12-05 2002-12-05 Exprimierungskontrolle unter verwendung von variabelen intergenischen sequenzen

Country Status (10)

Country Link
US (1) US7419659B2 (de)
EP (1) EP1451223B1 (de)
JP (2) JP2005522993A (de)
AT (1) ATE506374T1 (de)
AU (1) AU2002350901B2 (de)
CA (1) CA2466629C (de)
DE (1) DE60239823D1 (de)
ES (1) ES2365540T3 (de)
GB (1) GB0129105D0 (de)
WO (1) WO2003048208A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
US20050181479A1 (en) * 2005-03-04 2005-08-18 Medimmune, Inc. Periplasmic expression of antibodies using a single signal sequence
CA2608579C (en) * 2005-05-26 2019-09-10 Cytos Biotechnology Ag Scalable fermentation process
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
ME00832B (me) 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
NZ594315A (en) 2009-02-17 2013-05-31 Ucb Pharma Sa Antibody molecules having specificity for human ox40
US9109216B2 (en) 2009-09-24 2015-08-18 Ucb Pharma, S.A. Bacterial host strain
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
EP2542258A4 (de) 2010-03-04 2013-08-21 Vet Therapeutics Inc Auf cd52 gerichtete monoklonale antikörper
EP2545078A1 (de) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1-antikörper
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
JP5865002B2 (ja) * 2010-12-28 2016-02-17 東ソー株式会社 組換えプラスミドベクターおよびそれを用いたタンパク質の製造方法
HRP20180226T1 (hr) 2011-07-13 2018-03-09 Ucb Biopharma Sprl Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
EP2546267A1 (de) 2011-07-13 2013-01-16 UCB Pharma S.A. Bakterienwirtsstamm mit rekombinanter DsbC-Expression
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
TW201702271A (zh) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
JP7083124B2 (ja) * 2017-04-25 2022-06-10 国立大学法人弘前大学 ムコン酸産生形質転換微生物及びその利用
CN113646051A (zh) 2018-10-16 2021-11-12 Ucb生物制药有限责任公司 重症肌无力的治疗方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1243179A (en) * 1967-10-03 1971-08-18 Unimec Designs Ltd Improvements relating to mirror devices for motor vehicles
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US7018809B1 (en) * 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
AU7345094A (en) 1993-07-01 1995-01-24 Unilever Plc Oral compositions
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0124317D0 (en) * 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
AU2003293366A1 (en) * 2002-12-05 2004-06-30 Pharmacia Corporation Engineered fab'fragment anti-tumor necrosis factor alpha in combination with disease modifying anti-rheumatic drugs

Also Published As

Publication number Publication date
CA2466629C (en) 2011-07-05
EP1451223A2 (de) 2004-09-01
EP1451223B1 (de) 2011-04-20
JP2005522993A (ja) 2005-08-04
GB0129105D0 (en) 2002-01-23
WO2003048208A3 (en) 2003-12-31
ES2365540T3 (es) 2011-10-06
CA2466629A1 (en) 2003-06-12
WO2003048208A2 (en) 2003-06-12
JP2010207241A (ja) 2010-09-24
AU2002350901A1 (en) 2003-06-17
US7419659B2 (en) 2008-09-02
DE60239823D1 (de) 2011-06-01
AU2002350901B2 (en) 2008-11-06
US20060104949A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
ATE506374T1 (de) Exprimierungskontrolle unter verwendung von variabelen intergenischen sequenzen
ATE514717T1 (de) Rekombinante produktion von antikörpermischungen
ATE420964T1 (de) Polycistronische expression von antikörpern in cho zellen
ATE476504T1 (de) Verfahren zur herstellung von protein- bibliotheken und zur selektion von proteinen daraus
ATE87659T1 (de) Bindungsmolekuele mit einzelpolypeptidkette.
HRP20030087B1 (en) Anti-il-12 antibodies, compositions, methods and uses
ATE553125T1 (de) Herstellung eines multimeren proteins durch zellfusionsverfahren
CY1110494T1 (el) Μεταστροφες μεταβολικου ρυθμου σε ζυμωσεις που εκφραζουν ανασυνδυασμενες πρωτεϊνες
DK1032686T3 (da) Cellulase dannet af Actinomyceter og fremgangsmåde til frembringelse heraf
DE68921364D1 (de) Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA.
DE69829976D1 (de) Verfahren zur trocknung von kompetenten zellen
ATE438722T1 (de) Verfahren zur herstellung von proteinen unter reduktion von mannosephosphat in der zuckerkette und dadurch hergestelltes glykoprotein
ATE341621T1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
BR0315388A (pt) Molécula de ácido nucleico isolada de nicotiana, proteìna isolada de nicotiana, planta transgênica, método de produção de planta transgênica, e, método de seleção de uma planta contendo uma molécula de ácido nucleico
DK1078004T3 (da) Tetravalente antistof-konstrukter
DE69939901D1 (de) Verfahren und materialien zur herstellung von glucosamin
ATE119200T1 (de) Erhöhte produktion von proteinen in bakterien durch verwendung einer neuen ribosombindungsstelle.
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
ATE196317T1 (de) Rekombinantes vektor für die exozelluläre verwendung von in bacillus subtilis exprimierten einkettigen antikörpern
PT1306444E (pt) Metodo para producao de beta-caroteno
DE60214127D1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
DE69838459D1 (de) Für den licht-überempfinlichkeitsphaenotyp kodierende nukleotidsequenzen von tomaten, dadurch kodierte proteine und deren verwendungen
ATE539160T1 (de) Verfahren zur erhöhung der produktion von proteinen
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
DE60326716D1 (de) Promoter Sequenzen aus Moos und dessen Verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1451223

Country of ref document: EP